Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finotonlimab combination regimens as first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma
ChiCTR2500103475Phase 4Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of finotonlimab in head and neck squamous cell carcinoma (HNSCC) (3 cohorts), sponsored by Shanghai East Hospital. Primary endpoints: Objective Response Rate and Patients quality of life. Planned start May 2025; status: not yet recruiting.
02
Drugs
finotonlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500103475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103475.